A new study suggests heart health gains disappear in half the time it takes to build them up when people stop taking GLP-1 ...

An eye-opening study from the VA Saint Louis Healthcare System shows what quitting weight-loss drugs can do to the heart.

Researchers at the University of Bristol have identified a specific biological mechanism by which GLP-1 drugs, the same class ...

GLP-1 receptor agonists such as semaglutide are changing the way type 2 diabetes and obesity are treated. But these drugs have also shown a surprising ability to improve cardiovascular health — and ...

People take GLP-1 drugs like Wegovy, Ozempic, Mounjaro, and Zepbound for a variety of reasons, from controlling diabetes and ...

Researchers have found that adults who stop taking GLP-1 receptor agonist drugs such as semaglutide and tirzepatide face a measurable increase in heart attack, stroke, and death risk within months of ...

One major benefit of taking injected GLP-1 medications is a sizeable reduction in risk for heart attacks, strokes and other ...

The drug semaglutide, sold commercially as Ozempic or Wegovy, is well known for helping people lose significant amounts of weight quickly. Now the U.S. Food and Drug Administration has approved Wegovy ...

Trial results showing that a potent anti-obesity drug offers strong protection against serious heart problems have electrified researchers. They say that the findings could change how this and other ...

Following a rapid increase in popularity of GLP-1 drugs for diabetes and weight loss, such as semaglutide and tirzepatide, ...

Trial results showing that a potent anti-obesity drug offers strong protection against serious heart problems have electrified researchers. They say that the findings could change how this and other ...